Related Experiment Video
Updated: Jan 30, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
Published on: November 4, 2011
Larotrectinib: First Global Approval
1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.
Abstract:
Larotrectinib (VITRAKVI®) is an orally administered, small molecule, highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncology in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbour neurotrophic receptor tyrosine kinase (NTRK) gene fusions. In November 2018 larotrectinib received its first global approval in the USA for the treatment of adult and paediatric patients with solid tumours that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. A registration application for the use of larotrectinib in paediatric and adult patients with locally advanced or metastatic solid tumours with NTRK gene fusion proteins has been submitted in the EU. This article summarizes the milestones in the development of larotrectinib leading to its first approval for the treatment of adult and paediatric patients with solid tumours that have NTRK gene fusion.
Insights
Larotrectinib is a targeted therapy for cancers with NTRK gene fusions. This oral medication offers a new treatment option for adult and pediatric patients with these rare genetic alterations.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Larotrectinib is a small molecule inhibitor targeting tropomyosin receptor kinase (TRK).
- Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are key drivers in certain cancers.
- Targeted therapies offer precision medicine approaches for oncological conditions.
Purpose of the Study:
- To summarize the development milestones of larotrectinib.
- To highlight the regulatory approval of larotrectinib for NTRK gene fusion-positive cancers.
- To provide an overview of larotrectinib as a treatment for specific solid tumors.
Main Methods:
- Review of preclinical and clinical development data for larotrectinib.
- Analysis of regulatory submissions and approvals in the USA and EU.
- Summary of the drug's mechanism of action and target population.
Main Results:
- Larotrectinib received its first global approval in the USA in November 2018.
- The drug is indicated for adult and pediatric patients with NTRK gene fusion-positive solid tumors.
- A registration application has been submitted in the EU for similar indications.
Conclusions:
- Larotrectinib represents a significant advancement in targeted cancer therapy.
- The drug demonstrates efficacy in patients with NTRK gene fusions, irrespective of tumor type.
- Continued development and regulatory review are expanding access to this important treatment.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Global Climate Change
Introduction to Global Positioning System
Errors in Global Positioning System
Global Regulatory Systems
Field Application of Global Positioning System

